Predictors of edge stenosis after paclitaxel-eluting stent implantation
- PMID: 21285877
- DOI: 10.1097/MCA.0b013e328343fbff
Predictors of edge stenosis after paclitaxel-eluting stent implantation
Abstract
Background: Although edge stenosis (ES) is a main limitation of drug-eluting stents, the predictors for ES are not well known. We evaluated the predictors for ES after paclitaxel-eluting stent implantation.
Methods: One hundred and eleven angina patients (64 men; 62.2±8.4 years of age) were divided into ES (n=9) and non-ES groups (n=102). The clinical findings, procedural factors, and intravascular ultrasound (IVUS) parameters were analyzed.
Results: Although clinical characteristics were not different between groups, diabetes mellitus (DM) was more common in the ES group (P=0.002). The vessel, plaque, and lumen areas of the lesions were not different between groups; however, the vessel area of the proximal and distal reference artery was smaller in the ES group. Lesions with positive remodeling were more common in the ES group (P=0.015). On the basis of univariate analysis, predictors of ES included DM, lesions with positive remodeling, IVUS parameters, and procedural factors. After adjusting for clinical findings, angiographic factors, and IVUS parameters, the presence of DM [odds ratio (OR): 9.20; 95% confidence interval (CI): 1.40-60.62, P=0.021] and lesions with positive remodeling (OR: 5.93; 95% CI: 1.13-31.02, P=0.035) were independent predictors of ES. The lumen area in the distal 1 mm reference segment was a protective factor for ES (OR: 0.05; 95% CI: 0.00-0.74, P=0.029).
Conclusion: The risk of ES after paclitaxel-eluting stent implantation was higher in patients who had DM and lesions with positive remodeling. Of the IVUS parameters, the lumen area in the distal 1 mm reference segment was a protective factor against ES.
Similar articles
-
Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.JACC Cardiovasc Interv. 2009 Dec;2(12):1269-75. doi: 10.1016/j.jcin.2009.10.005. JACC Cardiovasc Interv. 2009. PMID: 20129555
-
A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.JACC Cardiovasc Interv. 2011 Mar;4(3):310-6. doi: 10.1016/j.jcin.2010.12.006. JACC Cardiovasc Interv. 2011. PMID: 21435609 Clinical Trial.
-
Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.Coron Artery Dis. 2008 Nov;19(7):507-11. doi: 10.1097/MCA.0b013e32830936d4. Coron Artery Dis. 2008. PMID: 18923247
-
Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus.EuroIntervention. 2011 May;7 Suppl K:K83-92. doi: 10.4244/EIJV7SKA15. EuroIntervention. 2011. PMID: 22027736 Clinical Trial.
-
Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses.Circ Cardiovasc Interv. 2012 Dec;5(6):763-71. doi: 10.1161/CIRCINTERVENTIONS.111.962878. Epub 2012 Nov 13. Circ Cardiovasc Interv. 2012. PMID: 23149332
MeSH terms
Substances
LinkOut - more resources
Full Text Sources